Citicoline turns up in discussions of addiction recovery more often than its evidence base warrants, and the reason is traceable. A cluster of trials run largely by one research group at UT Southwestern found encouraging signals in cocaine dependence, and those results got generalized outward into a broad claim that citicoline helps with cravings and substance-related cognitive damage. Alcohol is the substance most people are actually asking about. It is also the one where citicoline has been tested head-on in a randomized, double-blind, placebo-controlled trial, and that trial is worth reading carefully because it did not find what the surrounding hype implies.
Nothing here constitutes medical advice. Citicoline has not been approved by the FDA to diagnose, treat, cure, or prevent alcohol use disorder or any other condition. Alcohol use disorder is a serious medical condition with treatments that have real evidence behind them, and alcohol withdrawal can be dangerous without medical supervision.
Key Takeaways
- A 12-week randomized, double-blind, placebo-controlled trial of citicoline titrated to 2,000 mg/day in 62 adults with alcohol use disorder found no significant between-group differences on alcohol use, craving, cognition, or depressive symptoms [1].
- The trial’s own authors concluded that the favorable effects reported for cocaine use and cognitive disorders “do not appear to extend to alcohol use disorder” [1].
- Citicoline was well tolerated at 2,000 mg/day across 12 weeks, which is a meaningful safety data point even though the efficacy result was negative [1].
- The cocaine findings people generalize from are real but narrow: a 44-patient add-on trial in people with bipolar disorder and cocaine dependence found lower odds of a cocaine-positive urine at exit and better performance on one memory measure [2].
- A methamphetamine trial found improved depressive symptoms and better study retention, but specifically no difference in methamphetamine use or memory [3].
The Alcohol Trial, in Detail
The study was a 12-week, randomized, double-blind, parallel-group, placebo-controlled pilot of citicoline titrated to 2,000 mg/day in 62 adults aged 18 to 75 with alcohol use disorder, with 55 participants in the intent-to-treat analysis. This was not a casual design. Alcohol use was tracked with the Timeline Followback method plus liver enzymes, craving with the Penn Alcohol Craving Scale, cognition with a neurocognitive battery including the Rey Auditory Verbal Learning Test, and depressive symptoms with a self-report inventory [1].
The participants were genuinely drinking: across the assessment period, drinking days averaged 77% of assessed days. And the result was flat. Significant between-group differences were not observed on alcohol use, on craving, or on cognitive or depressive symptom measures. Citicoline was well tolerated [1].
The conclusion the authors drew is the sentence that matters most, because it is a direct correction of the generalization that had built up around the compound: this proof-of-concept study observed that citicoline was well tolerated but was not associated with a reduction in alcohol use or other outcomes compared with placebo, and the favorable effects reported with citicoline for cocaine use, cognitive disorders, and other conditions do not appear to extend to alcohol use disorder [1].
Where the “Citicoline Helps Cravings” Idea Came From
The idea is not invented, it is transplanted. A 2014 narrative review of citicoline in addictive disorders screened roughly 900 search hits and found only nine clinical studies to include, most of them investigating cocaine rather than alcohol. Its summary was that citicoline appears safe and well tolerated, appears to decrease craving, and is associated with reduced cocaine use, at least at high doses in patients with both bipolar disorder and cocaine dependence, with only limited data suggesting possible promise for alcohol and cannabis [4].
Read carefully, that review was already flagging the problem. Nine clinical studies total, mostly cocaine, mostly in a specific dual-diagnosis population, with alcohol explicitly listed under “limited data.” The review closed by calling for larger sample sizes and more complex designs [4]. Five years later a properly powered-for-a-pilot randomized alcohol trial was run, and it came back negative [1]. That is the research process working correctly. It is also exactly the update that supplement marketing tends not to make.
What the Cocaine and Methamphetamine Trials Actually Showed
Being fair to the positive data matters here, because the point is not that citicoline does nothing in addiction research. It is that the findings are narrower than the claims built on them.
The cocaine trial was a 12-week randomized, placebo-controlled, add-on, proof-of-concept study in 44 outpatients with a history of mania or hypomania plus cocaine dependence. Its primary aim was memory. It found a significant group effect favoring citicoline on one memory measure (the Rey Auditory Verbal Learning Test alternative word list), no significant differences on depression or mania ratings, and a significantly lower probability of a cocaine-positive urine at exit, with placebo participants having roughly 6.4 times higher odds of testing positive at exit [2]. That last number is genuinely striking. It also comes from 44 people with a specific co-occurring psychiatric diagnosis, in a study its own authors described as promising and warranting larger trials [2].
The methamphetamine trial randomized 60 adults with bipolar or unipolar depression plus methamphetamine dependence to citicoline 2,000 mg/day or placebo for 12 weeks. Citicoline produced significantly greater improvement in clinician-rated depressive symptoms and significantly longer survival in the study with higher completion rates. It produced no significant difference in memory and no significant difference in methamphetamine use [3]. The retention finding is interesting in its own right, since staying in treatment is a real clinical outcome. But an honest summary is that this trial found an antidepressant signal and not a substance-use signal.
Putting the Pattern Together
Across four trials, the results do not line up into “citicoline reduces cravings.” They line up into something more specific and less marketable: a possible effect on cocaine use in a dual-diagnosis population, a possible antidepressant effect in a different dual-diagnosis population, no effect on methamphetamine use, and no effect on any alcohol outcome measured. All of the trials share limitations worth noting: small samples, proof-of-concept designs, largely one research group, and populations selected for co-occurring mood disorders rather than substance use alone, which limits how far any of it generalizes to someone without a psychiatric diagnosis.
The most defensible reading is that citicoline’s addiction research is early, mixed, and has already produced one clear negative result in the substance most people are asking about.
What About Alcohol-Related Cognitive Impairment?
This deserves a separate note, because it is a different question from whether citicoline reduces drinking. Heavy long-term alcohol use can damage cognition, and citicoline’s phospholipid and cholinergic mechanisms make it a plausible candidate for supporting recovery of that damage. The alcohol trial did measure cognition with a neurocognitive battery, and found no significant between-group difference there either [1]. So the one direct test that has been run does not support that use case, though it was a 12-week study in people who were largely still drinking, not a study of cognitive recovery in sustained abstinence, which nobody appears to have run.
The Practical Bottom Line
Alcohol use disorder has treatments with substantially better evidence than citicoline, including FDA-approved medications and structured behavioral treatment. Nothing in the citicoline literature justifies substituting a supplement for those. The trial that tested this question directly is negative, and it was run by the same group whose earlier cocaine work generated the optimism in the first place, which makes it hard to dismiss as an outlier. Anyone dealing with alcohol use should be talking to a clinician, not evaluating supplements, and alcohol withdrawal in particular can be medically dangerous to manage alone.
Frequently Asked Questions
Does citicoline reduce alcohol cravings?
The one randomized, double-blind, placebo-controlled trial to test this, using 2,000 mg/day for 12 weeks in 62 adults with alcohol use disorder, found no significant difference from placebo on craving as measured by the Penn Alcohol Craving Scale, or on any other outcome measured [1].
Why do people say citicoline helps with addiction then?
The claim is generalized from cocaine research. A 44-patient add-on trial in people with bipolar disorder and cocaine dependence found lower odds of a cocaine-positive urine at exit [2], and a 2014 review found most citicoline addiction research was in cocaine, with alcohol data explicitly described as limited [4]. The alcohol-specific trial that followed was negative [1].
Does citicoline help cognition damaged by heavy drinking?
The alcohol trial included a neurocognitive battery and found no significant between-group difference on cognitive measures [1]. That was a 12-week study in people largely still drinking; citicoline for cognitive recovery during sustained abstinence does not appear to have been tested.
Was citicoline safe in these trials?
Citicoline was described as well tolerated at 2,000 mg/day over 12 weeks in the alcohol trial [1], and in the cocaine trial no participants were reported to have discontinued because of medication side effects [2]. Tolerability and efficacy are separate questions, and only the tolerability finding was positive for alcohol.
Did any addiction trial show a positive result?
Yes, but narrowly. The cocaine trial found improvement on one memory measure and lower odds of a cocaine-positive urine at exit in patients with co-occurring bipolar disorder [2]. A methamphetamine trial found improved depressive symptoms and better study retention but specifically no difference in methamphetamine use or memory [3].
References
- Brown ES, Van Enkevort E, Kulikova A, et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline in Patients with Alcohol Use Disorder. Alcohol Clin Exp Res (2019). PMID 30457668
- Brown ES, Gorman AR, Hynan LS. A randomized, placebo-controlled trial of citicoline add-on therapy in outpatients with bipolar disorder and cocaine dependence. J Clin Psychopharmacol (2007). PMID 17873684
- Brown ES, Gabrielson B. A randomized, double-blind, placebo-controlled trial of citicoline for bipolar and unipolar depression and methamphetamine dependence. J Affect Disord (2012). PMID 22974472
- Wignall ND, Brown ES. Citicoline in addictive disorders: a review of the literature. Am J Drug Alcohol Abuse (2014). PMID 24950234
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice. As an Amazon Associate we earn from qualifying purchases.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
